Onxeo - Termination of coverage
Edison Investment Research is terminating coverage on Steakholder Foods (formerly known as MeaTech) (MITC), Mesoblast (MSB), Bluglass (BLG), InMed...
672 Views
Onxeo - Expanding AsiDNA R&D programme
Currently, Onxeo is running a triple combination Phase Ib study (n=6; AsiDNA plus carboplatin plus paclitaxel). Top line results should be...
66 Views
Onxeo - Green light for Ph Ib/II after DRIIV-1 interim data
Onxeo’s lead asset, AsiDNA, is currently being tested in a Phase I DRIIV-1 trial in patients with advanced solid tumours (n=36). Interim results...
68 Views
Onxeo - Phase I with AsiDNA iv starts; first data in H218
On 24 April, Onxeo announced that the first patient had been treated with AsiDNA, a first-in-class DNA break repair inhibitor, via systemic...
78 Views
Onxeo - Introducing platON; AsiDNA approaches Phase I
Onxeo has experienced a volatile 2017 mainly due to Livatag’s Phase III ReLive not meeting its primary endpoint. The out-licensing of Validive,...
77 Views
No more insights